Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule administered intramuscularly in healthy adults. AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure.
{iframe}https://pipelinereview.com/index.php/2019032070800/Vaccines/Emergent-BioSolutions-Initiates-Phase-3-Clinical-Study-to-Evaluate-AV7909-for-Post-Exposure-Prophylaxis-of-Anthrax.html{/iframe}